How many drugs treat Psoriasis with arthropathy?

Drug Landscape tracks 10 marketed treatments for Psoriasis with arthropathy (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/psoriasis-with-arthropathy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Psoriasis with arthropathy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psoriasis with arthropathy (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Psoriasis with arthropathy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Otezla	APREMILAST	Amgen	Phosphodiesterase 4 Inhibitor [EPC]	PDE4	2014-01-01
Simponi	GOLIMUMAB	Centocor Ortho Biotech Inc	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
Cimzia	CERTOLIZUMAB PEGOL	UCB	Tumor Necrosis Factor Blocker [EPC]	TNFα	2008-01-01
Abrilada	Adalimumab-Afzb	AbbVie	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Arava	LEFLUNOMIDE	Sanofi	Antirheumatic Agent [EPC]	Cytochrome P450 1A2	1998-01-01
Remicade	INFLIXIMAB	Johnson & Johnson	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	1998-01-01
Enbrel	etanercept	Immunex	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	1998-01-01
Remicade	Infliximab-Dyyb	Johnson & Johnson	TNF blocker	Tumor Necrosis Factor alpha (TNFα)	1998-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson · 4 drugs in Psoriasis with arthropathy
· 4 drugs in Psoriasis with arthropathy
Pfizer · 2 drugs in Psoriasis with arthropathy
AbbVie · 2 drugs in Psoriasis with arthropathy
Generic (originally Schering) · 2 drugs in Psoriasis with arthropathy
Centocor Ortho Biotech Inc · 1 drug in Psoriasis with arthropathy
Hannover Medical School · 1 drug in Psoriasis with arthropathy
Biocon Biologics UK Ltd · 1 drug in Psoriasis with arthropathy
Generic (originally Upjohn/Pfizer) · 1 drug in Psoriasis with arthropathy
BOEHRINGER INGELHEIM · 1 drug in Psoriasis with arthropathy
Generic (originally Merck/Upjohn) · 1 drug in Psoriasis with arthropathy
Generic (originally Merck) · 1 drug in Psoriasis with arthropathy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Psoriasis with arthropathy:

Cite this brief

Drug Landscape (2026). Psoriasis with arthropathy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/psoriasis-with-arthropathy. Accessed 2026-06-10.

Psoriasis with arthropathy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing